title: Application of an in vitro OAT assay in drug design and optimization of renal clearance.
abstract: 1. Optimization of renal clearance is a complex balance between passive and active processes mediated by renal transporters. This work aimed to characterize the interaction of a series of compounds with rat and human organic anion transporters (OATs) and develop quantitative structure-activity relationships (QSARs) to optimize renal clearance. 2. In vitro inhibition assays were established for human OAT1 and rat Oat3 and rat in vivo renal clearance was obtained. Statistically significant quantitative relationships were explored between the compounds' physical properties, their affinity for OAT1 and oat3 and the inter-relationship with unbound renal clearance (URC) in rat. 3. Many of the compounds were actively secreted and in vitro analysis demonstrated that these were ligands for rat and human OAT transporters (IC50 values ranging from <1 to >100 µM). Application of resultant QSAR models reduced renal clearance in the rat from 24 to <0.1 ml/min/kg. Data analysis indicated that the properties associated with increasing affinity at OATs are the same as those associated with reducing URC but orthogonal in nature. 4. This study has demonstrated that OAT inhibition data and QSAR models can be successfully used to optimize rat renal clearance in vivo and provide confidence of translation to humans.
authors.affiliation: Department of Discovery DMPK, AstraZeneca Charnwood , Bakewell Road, Loughborough, Leicestershire , UK .
authors.forename: Matthew G
authors.initials: MG
authors.lastname: Soars
authors.forename: Patrick
authors.initials: P
authors.lastname: Barton
authors.forename: Lisa L
authors.initials: LL
authors.lastname: Elkin
authors.forename: Kathleen W
authors.initials: KW
authors.lastname: Mosure
authors.forename: Joanne L
authors.initials: JL
authors.lastname: Sproston
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Riley
mesh_terms: D000818:Animals; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D057809:HEK293 Cells / Q000187:drug effects; D006801:Humans; D020128:Inhibitory Concentration 50; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D027362:Organic Anion Transport Protein 1 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D029362:Organic Anion Transporters, Sodium-Independent / Q000037:antagonists & inhibitors*; D010599:Pharmacokinetics; D021281:Quantitative Structure-Activity Relationship; D051381:Rats; D065667:Renal Elimination / Q000187:drug effects*
chemical_list: D027362:Organic Anion Transport Protein 1; D029362:Organic Anion Transporters, Sodium-Independent; C114338:organic anion transport protein 3
keywords: Clearance; pharmacokinetics; renal; transporters